Fig. 3

In vitro analyses of LV-F8BDD expression under different promoters in ECs and megakaryocytes. A Illustration of transduction efficiencies (VCN/cell) of the different LV promoter constructs (n = 3). B, C mRNA levels as percentages (%) of F8/GAPDH mRNA in ECs (B) and megakaryocytes (C) determined by gel electrophoresis (left) and RT-qPCR (right) (n = 3). D Protein concentrates detected using a human FVIII ELISA kit in ECs and megakaryocytes (n = 3). E FVIII activities determined by FVIII: C chromogenic assay in ECs and megakaryocytes (n = 3). The differences in characteristics between groups were analyzed using the one way Welch ANOVA tests with Games-Howell post hoc tests (A–C, E) and Kruskal–Wallis tests (D); *p < 0.05, **p < 0.01, ****p < 0.0001, n.s., no significant difference